We are live on ! Find out more
Baillie Gifford & Co

Baillie Gifford & Co Portfolio holdings

AUM $110B
1-Year Est. Return 4.8%
 

Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.

This Fund
S&P 500
This Quarter Est. Return
-25.13%
1 Year Est. Return
+4.8%
3 Year Est. Return
+123.53%
5 Year Est. Return
+125.55%
10 Year Est. Return
+1,754.37%
AUM
$97.5B
AUM Growth
-$45.1B
Cap. Flow
-$1.57B
Cap. Flow %
-1.61%
Top 10 Hldgs %
35.7%
Holding
526
New
28
Increased
112
Reduced
187
Closed
33

Top Buys

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$691M
2
MELI icon
Mercado Libre
MELI
+$341M
3
SPOT icon
Spotify
SPOT
+$335M
4
WIX icon
WIX.com
WIX
+$315M
5
RBLX icon
Roblox
RBLX
+$233M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$334M
2
CBRE icon
CBRE Group
CBRE
+$310M
3
AMZN icon
Amazon
AMZN
+$302M
4
NVDA icon
NVIDIA
NVDA
+$296M
5
TTD icon
Trade Desk
TTD
+$255M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 27.49%
2 Healthcare 25.5%
3 Technology 17.13%
4 Communication Services 10.66%
5 Financials 7.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NKTR icon
451
Nektar Therapeutics
NKTR
$2.58B
$5K ﹤0.01%
92
NNDM
452
Nano Dimension
NNDM
$343M
$5K ﹤0.01%
1,600
OM icon
453
Outset Medical
OM
$90.8M
$5K ﹤0.01%
20
-3
-13% -$1.29K
OXM icon
454
Oxford Industries
OXM
$552M
$5K ﹤0.01%
55
-18
-25% -$1.62K
SUMO
455
DELISTED
Sumo Logic, Inc. Common Stock
SUMO
$5K ﹤0.01%
726
DCT
456
DELISTED
Duck Creek Technologies, Inc. Common Stock
DCT
$5K ﹤0.01%
355
AGIO icon
457
Agios Pharmaceuticals
AGIO
$1.93B
$4K ﹤0.01%
186
AXGN icon
458
Axogen
AXGN
$2.5B
$4K ﹤0.01%
444
BLUE
459
DELISTED
bluebird bio
BLUE
$4K ﹤0.01%
43
TSVT
460
DELISTED
2seventy bio
TSVT
$4K ﹤0.01%
286
VERI icon
461
Veritone
VERI
$122M
$4K ﹤0.01%
649
ZD icon
462
Ziff Davis
ZD
$1.98B
$4K ﹤0.01%
53
ZYXI
463
DELISTED
Zynex
ZYXI
$4K ﹤0.01%
481
HCSG icon
464
Healthcare Services Group
HCSG
$1.53B
$3K ﹤0.01%
157
INGN icon
465
Inogen
INGN
$164M
$3K ﹤0.01%
141
TWOU
466
DELISTED
2U Inc
TWOU
$3K ﹤0.01%
11
TSP
467
DELISTED
TuSimple Holdings Inc. Class A Common Stock
TSP
$3K ﹤0.01%
349
ONEM
468
DELISTED
1Life Healthcare
ONEM
$3K ﹤0.01%
445
AI icon
469
C3.ai
AI
$1.59B
$2K ﹤0.01%
117
CGNT icon
470
Cognyte Software
CGNT
$680M
$2K ﹤0.01%
369
CRH icon
471
CRH
CRH
$66.8B
$2K ﹤0.01%
+60
New +$2.33K
FSLY icon
472
Fastly Inc
FSLY
$3.66B
$2K ﹤0.01%
205
GAN
473
DELISTED
GAN Ltd
GAN
$2K ﹤0.01%
572
MARA icon
474
Marathon Digital Holdings
MARA
$3.9B
$2K ﹤0.01%
343
RIO icon
475
Rio Tinto
RIO
$164B
$2K ﹤0.01%
+38
New +$2.72K

Similar funds

Baillie Gifford & Co's Q2 2022 Portfolio in Review

As of Q2 2022, Baillie Gifford & Co held 526 positions worth $97.5B, down 32% from $143B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Baillie Gifford & Co's Q2 2022 filing shows 28 new, 112 increased, 187 reduced and 33 closed positions. Its largest new stake was Hershey: 94,977 shares worth $20.4M. The largest sale was Tesla, an estimated $334M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 27% of assets, down from 28% a quarter earlier, followed by Healthcare and Technology.

  • Baillie Gifford & Co's largest Q2 2022 buy was Hershey: 94,977 shares worth $20.4M.
  • Baillie Gifford & Co added most to Royalty Pharma in Q2 2022, an estimated $691M increase.
  • Baillie Gifford & Co's biggest Q2 2022 reduction was Tesla, cutting an estimated $334M.
  • Baillie Gifford & Co fully exited iShares Silver Trust in Q2 2022, selling an estimated $21.2M.
  • Baillie Gifford & Co's ten largest holdings make up 36% of its $97.5B portfolio in Q2 2022.
  • Baillie Gifford & Co opened 28 new positions and closed 33 in Q2 2022.
  • Baillie Gifford & Co's portfolio value fell 32% quarter-over-quarter to $97.5B.

Based on Baillie Gifford & Co's 13F filing for Q2 2022, filed 8 Aug 2022.